Literature DB >> 36138277

Diversity of Participation in Clinical Trials and Influencing Factors: Findings from the Health Information National Trends Survey 2020.

Daniel M Walker1,2, Christine M Swoboda3, Karen Shiu-Yee3, Willi L Tarver3,4, Timiya S Nolan5,6, Joshua J Joseph7.   

Abstract

BACKGROUND: Clinical trial diversity is critical to advance health and health equity. Research addressing the discrepancy between goals of achieving clinical trial diversity and realities of study enrollment remains underdeveloped.
OBJECTIVE: This study aims to examine the association between race/ethnicity and clinical trial invitation, participation, knowledge, and sources of influence on clinical trial participation. DESIGN AND PARTICIPANTS: A cross-sectional, observational study using nationally representative data from 3689 US adults (≥ 18 years of age) who responded to the Health Information National Trends Survey fielded from February 24 to June 15, 2020. MAIN MEASURES: Primary outcomes included clinical trial invitation, participation, knowledge, and sources of influence on participation. The independent variable of interest is self-reported race/ethnicity. KEY
RESULTS: Respondents identifying as non-Hispanic Black (relative to non-Hispanic White) had higher odds of being invited into a clinical trial (adjusted odds ratio: 2.0, 95% confidence interval (CI): 1.1, 3.7), but no differences in odds of participation were observed by race/ethnicity. Respondents from all races/ethnicities reported that personal healthcare providers were the most trusted source of clinical trial information. Hispanic (marginal effect (ME): - 0.09; 95% CI: - 0.16, - 0.03), non-Hispanic Black (ME: - 0.11; 95% CI: - 0.18, - 0.04), and non-Hispanic other (ME: - 0.11; 95% CI: - 0.19, - 0.02) respondents had lower odds than non-Hispanic White respondents of saying they would be influenced "a lot" by their doctor encouraging participation. Non-Hispanic Black respondents had significantly lower odds (relative to non-Hispanic White) of indicating family encouragement would influence their clinical trial participation decision "a lot" (ME: - 0.09; 95%: CI: - 0.14, - 0.03).
CONCLUSION: While personal healthcare providers were trusted sources of information, racial/ethnic minority populations noted lower odds of clinical trial participation influence from providers and family. Thus, it is imperative for the healthcare, government, and industry organizations to build trust in medicine and science.
© 2022. The Author(s), under exclusive licence to Society of General Internal Medicine.

Entities:  

Keywords:  HINTS; NCI; clinical trials; diversity; health equity

Year:  2022        PMID: 36138277     DOI: 10.1007/s11606-022-07780-2

Source DB:  PubMed          Journal:  J Gen Intern Med        ISSN: 0884-8734            Impact factor:   6.473


  22 in total

1.  Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril.

Authors:  Jackson T Wright; J Kay Dunn; Jeffrey A Cutler; Barry R Davis; William C Cushman; Charles E Ford; L Julian Haywood; Frans H H Leenen; Karen L Margolis; Vasilios Papademetriou; Jeffrey L Probstfield; Paul K Whelton; Gabriel B Habib
Journal:  JAMA       Date:  2005-04-06       Impact factor: 56.272

2.  Addressing Systemic Racism Through Clinical Preventive Service Recommendations From the US Preventive Services Task Force.

Authors:  Chyke A Doubeni; Melissa Simon; Alex H Krist
Journal:  JAMA       Date:  2021-02-16       Impact factor: 56.272

3.  Diversity in clinical trials: an opportunity and imperative for community engagement.

Authors:  Darrell M Gray; Timiya S Nolan; John Gregory; Joshua J Joseph
Journal:  Lancet Gastroenterol Hepatol       Date:  2021-08

4.  When will clinical trials finally reflect diversity?

Authors:  Todd C Knepper; Howard L McLeod
Journal:  Nature       Date:  2018-05       Impact factor: 49.962

5.  Overcoming Lack of Diversity in Cardiovascular Clinical Trials: A New Challenge and Strategies for Success.

Authors:  Rebecca F Ortega; Clyde W Yancy; Roxana Mehran; Wayne Batchelor
Journal:  Circulation       Date:  2019-11-18       Impact factor: 29.690

6.  A Model of Cancer Clinical Trial Decision-making Informed by African-American Cancer Patients.

Authors:  Jennifer A Wenzel; Olive Mbah; Jiayun Xu; Gyasi Moscou-Jackson; Haneefa Saleem; Kwame Sakyi; Jean G Ford
Journal:  J Racial Ethn Health Disparities       Date:  2015-06

7.  Differences in Hypertension Medication Prescribing for Black Americans and Their Association with Hypertension Outcomes.

Authors:  Hunter K Holt; Ginny Gildengorin; Leah Karliner; Valy Fontil; Rajiv Pramanik; Michael B Potter
Journal:  J Am Board Fam Med       Date:  2022 Jan-Feb       Impact factor: 2.657

8.  Perceived Institutional Barriers Among Clinical and Research Professionals: Minority Participation in Oncology Clinical Trials.

Authors:  Soumya J Niranjan; Jennifer A Wenzel; Michelle Y Martin; Mona N Fouad; Selwyn M Vickers; Badrinath R Konety; Raegan W Durant
Journal:  JCO Oncol Pract       Date:  2021-05

9.  Strategies to improve diversity, equity, and inclusion in clinical trials.

Authors:  Justine M Kahn; Darrell M Gray; Jill M Oliveri; Chasity M Washington; Cecilia R DeGraffinreid; Electra D Paskett
Journal:  Cancer       Date:  2021-09-08       Impact factor: 6.921

Review 10.  Re-thinking the inclusion of race in British hypertension guidance.

Authors:  Dipesh P Gopal; Grace N Okoli; Mala Rao
Journal:  J Hum Hypertens       Date:  2021-09-10       Impact factor: 3.012

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.